Truist Securities Reiterates Buy Rating on Ultragenyx Pharma (RARE)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Leerink on Ultragenyx Pharma (RARE): 'DTX401 Rolling BLA Submitted, Setting Up Launch for Underappreciated Program'
December 31, 2025 9:23 AM ESTLeerink Partners analyst Joseph Schwartz reiterated an Outperform rating and $70.00 price target on Ultragenyx Pharma (NASDAQ: RARE).
The analyst comments "In line with expectations, Ultragenyx (RARE, OP) completed the rolling submission of DTX401's BLA, setting up a potential launch in 2026; we continue to think this is an underappreciated asset within the company, which may begin to get more... More
Ultragenyx Pharma (RARE) PT Lowered to $70 at Leerink Partners
December 29, 2025 3:27 PM ESTLeerink Partners analyst Joseph Schwartz lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $70.00 (from $80.00) while maintaining a Outperform rating.
... MoreUltragenyx Pharma (RARE) PT Lowered to $47 at Baird
December 29, 2025 12:48 PM ESTBaird analyst Joel Beatty lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $47.00 (from $72.00) while maintaining a Outperform rating.
The analyst comments "Negative on clinical trial update. This morning, Ultragenyx announced that neither the ORBIT nor COSMIC study of setrusumab produced a statistically... More
William Blair Reiterates Outperform Rating on Ultragenyx Pharma (RARE)
December 29, 2025 12:04 PM ESTWilliam Blair analyst Sami Corwin reiterated an Outperform rating and {REMOVEPT} price target on Ultragenyx Pharma (NASDAQ: RARE).
The analyst comments "Stock thoughts: W e are disappointed and surprised by today s news given setrusumab s ef ficacy in the Phase II portion of the Orbit study and the increased enrollment of patients with severe disease subtypes (type III/IV) in the Phase III study ,... More
